Diagnosing Epilepsy To EffeCT Change

Conditions

• Epilepsy
• Epilepsy (Treatment Refractory)

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) — DEVICE
  The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry unit that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.

Study Details

The purpose of this research is to address the challenges of diagnosing and long-term management of epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research will compare the Minder System to standard of care in providing reliable seizure data. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants will consent to join the study and be implanted with the Minder device; or consent to join the study and continue with their Standard of Care (SOC) as a control group. Participants chose to be implanted with the Minder device will have the device implanted under their scalp. After implantation, participants will be randomly assigned to a group where their treating physician will have access to the EEG data collected by the Minder System or a group where their treating physician does not have access to the EEG data collected by the Minder System. Participants receiving the Minder System will not know which group they are in (blinded) until the study ends. All participants will continue to be followed by their treating physician and undergo assessments and visits until enough information is available to determine a treatment plan or the 6-month follow-up visit.

Key Dates

Start date

Dec 23, 2025

Status verified

May 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

210 participants (estimated)

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Minder System Treatment Arm
• Placebo Comparator: Minder System Control Arm
• No Intervention: Standard of Care Arm

Primary Outcome Measure

Compare the proportion of participants receiving the Minder System with those receiving Standard of Care (SOC) as a means of obtaining an actionable event based on clinical data (i.e. Minder EEG data, non-Minder EEG data, SOC assessments, etc.). [ Time Frame: 6 months ]

Central Contacts

• Epiminder, Director of Clinical Trials
  800-717-3185
  [email protected]

Locations (18)

Find similar trials in Phoenix, AZ

Related Studies

• Human Epilepsy Genetics--Neuronal Migration Disorders Study
  Recruiting · Harvard University Faculty of Medicine · Boston, Massachusetts
• Genetics of Epilepsy and Related Disorders
  Recruiting · Boston Children's Hospital · Boston, Massachusetts
• Genetic Markers of Cardiovascular Disease in Epilepsy
  Recruiting · Mayo Clinic · Rochester, Minnesota
• VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems
  Recruiting · University of Louisville · Louisville, Kentucky